Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1216 to 1230 of 1961 results for nice guidelines

  1. t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)

    NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .

  2. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

  3. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (HTG571)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.

  4. moorLDLS-BI for burn depth assessment (MIB251)

    NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .

  5. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  6. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (HTG549)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.

  7. OxyMask for delivering oxygen therapy (MIB160)

    NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .

  8. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

  9. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  10. Public board meeting agenda and papers March 2025

    Agenda and papers of the NICE public board meeting on 19 March 2025

  11. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .

  12. Is obesity an independent risk factor for perinatal morbidity and mortality?

    on the woman's preference and obstetric indications in line with the NICE guideline on intrapartum care for health women...

  13. Our principles

    The principles that guide the development of NICE guidance and standards.

  14. Get involved

    Tell us what matters to you, your organisation or your community.

  15. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making